Efficacy of NVX-CoV2373 Covid-19 Vaccine against the B.1.351 Variant

Cited by (629)

Items 601–629 of 629

1. COVID-19 Vaccines: Development, Efficacy, Safety, and Global Distribution
   Bilegtsaikhan Tsolmon · 2023 · Pacific International Journal
2. Causal Inference for Estimation of Vaccine Effects from Time-to-Event Data
   Zhouxuan Li, Kai Zhang, Yashar Talebi, Hulin Wu, Wenyaw Chan, Eric Boerwinkle, Momiao Xiong · 2023 · medRxiv
3. Nanoscale Vaccines for the Prevention of COVID-19
   Mir Javid Iqbal, Tooba Hamdani, Husain Z. Attarwala, Mansoor M. Amiji · 2023 · AAPS advances in the pharmaceutical sciences series
4. Study Effects of Covid_19 Transmission And The Characteristics On Fertility
   Shaymaa Galeel Shamran · 2023 · BASRA JOURNAL OF SCIENCE
5. Oral administration of a recombinant modified RBD antigen of SARS-CoV-2 as a possible immunostimulant for the care of COVID-19
   Norma A. Valdez‐Cruz, Diego Rosiles-Becerril, Constanza Estefanía Martínez-Olivares, Enrique García‐Hernández, Laura Cobos-Marín, Daniel Garzón, Francisco E. López-Salas, Guadalupe Zavala, Axel Luviano, Alejandro Olvera et al. · 2024 · Microbial Cell Factories
6. SARS-CoV-2 y la vacunación: situación actual y futuros escenarios
   Daniel Echeverri-De la Hoz, Alejandra García, Máttar, Salim · 2023
7. An arsenal of naturopathic compounds for the treatment of COVID-19: A comprehensive review
   Melike Tepe, Kübra Feyza Erol, Ayşe Esra Karadağ, Mustafa Güzel · 2024 · Journal of Phytomolecules and Pharmacology
8. The Protective Efficacy of a SARS-CoV-2 Vaccine Candidate B.1.351V against Several Variant Challenges in K18-hACE2 Mice
   J.E. Yang, Huifen Fan, Anna Yang, Wenhui Wang, Xin Hua Wan, Fengjie Lin, Dongsheng Yang, Jie Wu, Kaiwen Wang, Wei Li et al. · 2024 · Vaccines
9. Causal Inference of the Effect of Vaccination on COVID-19 Disease Severity and Need for Intensive Care Unit Admission Among Hospitalized Patients in an African Setting
   Eskedar Kebede Belayneh, Tigist Workneh Leulseged, Blen Solomon Teklu, Bersabel Hilawi Tewodros, Muluken Zeleke Megiso, Edengenet Solomon Weldesenbet, Mefthe Fikru Berhanu, Yohannes Shiferaw Shaweno, Kirubel Tesfaye Hailu · 2024 · Cureus
10. Recommend existing COVID-19 vaccines to reduce serious illness but new vaccines are needed to prevent transmission
    Simon S.-P. Fung · 2024 · Drugs & Therapy Perspectives
11. COVID-19 vaccines: A comprehensive review of safety and efficacy
    Zhipeng Yan, Ming Yang, Ching‐Lung Lai · 2025 · Elsevier eBooks
12. Nanostructured lipid-based adjuvants and delivery systems for antiviral vaccine development
    Yanqi Zhao, Zijian Cheng, Dian Cai, Yue-Lin Fang, Jian Xu, Hanzhi Dai, Wenqi Liu, Xinxin Zhang · 2025 · Chinese Chemical Letters
13. An updated overview of clinical trials, official approval, and risks for the application of nanomaterials in COVID-19 management
    Nour Elhouda Daoudi, Faiza Souna, Salah‐eddine Azizi, Ilyass Alami Merrouni, Mohammed Dalli · 2025 · Elsevier eBooks
14. Additional file 1 of The immune evasion ability of Delta variant is comparable to that of Beta variant in South Africa
    He, Daihai, Boqiang Chen, Zhao, Shi, Stone, Lewi · 2023 · Figshare
15. Additional file 2 of COVID-19 vaccination efficacy in numbers including SARS-CoV-2 variants and age comparison: a meta-analysis of randomized clinical trials
    Marharyta Sobczak, Rafał Pawliczak · 2022 · Figshare
16. Additional file 1 of Headache onset after vaccination against SARS-CoV-2: a systematic literature review and meta-analysis
    Matteo Castaldo, Marta Waliszewska‐Prosół, Maria Koutsokera, Micaela Robotti, Marcin Straburzyński, Loukia Apostolakopoulou, Mariarita Capizzi, Oneda Çibuku, Fidel Dominique Festin Ambat, Ilaria Frattale et al. · 2022 · Figshare
17. Additional file 1 of Effectiveness of COVID-19 vaccines against SARS-CoV-2 variants of concern: a systematic review and meta-analysis
    Baoqi Zeng, Gao, Le, Q X Zhou, Kai Yu, Sun, Feng · 2022 · Figshare
18. Additional file 1 of COVID-19 GPH: tracking the contribution of genomics and precision health to the COVID-19 pandemic response
    Yu, Wei, Emily Drzymalla, MARTA L. GWINN, Khoury, Muin J. · 2022 · Figshare
19. Additional file 1 of COVID-19 vaccination efficacy in numbers including SARS-CoV-2 variants and age comparison: a meta-analysis of randomized clinical trials
    Marharyta Sobczak, Rafał Pawliczak · 2022 · Figshare
20. A self-assembled nanoparticle vaccine displaying chimeric and trimeric RBD-HRC elicits broad-spectrum neutralizing antibodies against multiple coronaviruses
    Didi Wan, Lei Li, Feng He, Mengyu Wang, Shuo Jia, Pengyu Zhang, Jiaxu Wang, Junxia Yang, Y.Y. Zhang, Boya Ji et al. · 2026 · Microbiology Spectrum
21. Targeting the Epithelial Alarmin Axis with Biomedical Nanoparticles: A New Frontier in Allergic Asthma Therapy
    Yifei Yang · 2026 · International Journal of Nanomedicine
22. Conclusion and future prospective of protein-based nanoparticles
    Alookika Agarwal, Payel Shil, K.G. Abishek, Garima Gupta, Prakash Kumar Sarangi, Muskan Leharwani, Prashant Kesharwani, Ulduza Ahmad Gurbanova, Aziz Eftekhari, Rambabu Dandela · 2026 · Elsevier eBooks
23. N6-Adenosine Methylation of a Single Site in SARS-CoV-2 5′-UTR Promotes Translation
    Ammar Aly, Gary Scott, Mario Calderon, Ali Pejmun Haghighi · 2026 · eLife
24. N6-Adenosine Methylation of a Single Site in SARS-CoV-2 5′-UTR Promotes Translation
    Ammar Aly, Gary Scott, Mario Calderon, Ali Pejmun Haghighi · 2026 · eLife
25. Immunogenicity and safety of SARS-COV-2 recombinant protein subunit vaccine (INDOVAC) in west Sumatera Province adolescents: A phase 3, observer blind, randomized, active-controlled
    Asrawati Nurdin, Bernie Endyarni Medise, Cahya Dewi Satria, Mita Puspita, Raveinal, Andani Eka Putra, Finny Fitry Yani, Fenty Anggrainy, Afriani, Linosefa et al. · 2026 · Vaccine X
26. A Population-Based HIV Vaccine Efficacy Trial Design: Statistical Framework and Design Considerations
    Holly Janes, Fei Gao, Susan Buchbinder, Charles Shey Wiysonge, Kimberly Louis, Blossom Napoleon, Amelia Mfiki, Derrick Mapp, Glenda Gray · 2026 · Vaccines
27. Serological Profile of SARS-CoV-2 IgG Antibodies in Vaccinated and Unvaccinated Hospital Workers in Dakar, Senegal
    Cheikh Daouda Fall, Ousseynou Boye, Doudou Georges Massar Niang, Khadidiatou Sarr Fall, Pape Samba Danfa, Moustapha Mbow, Babacar Mbengué, Sylla Niang Maguette · 2026 · World Journal of Vaccines
28. Reduced antibody activity against SARS-CoV-2 B.1.617.2 delta virus
    Michael Diamond · 2025 · ImmPort
29. Protective activity of mRNA vaccines
    Florian Krammer · 2024 · ImmPort